Revvity (RVTY) – Research Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Revvity (NYSE: RVTY) in the last few weeks:

• 7/6/2026 – Revvity had its “outperform” rating reaffirmed by Evercore Inc. They now have a $125.00 price target on the stock.
• 7/6/2026 – Revvity was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/26/2026 – Revvity is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $115.00 price target on the stock.
• 6/25/2026 – Revvity was upgraded by Sanford C. Bernstein to “hold”.
• 6/24/2026 – Revvity was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 6/2/2026 – Revvity is now covered by Wolfe Research. They set a “peer perform” rating on the stock.

Revvity Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 7th. Stockholders of record on Friday, July 17th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Friday, July 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. Revvity’s dividend payout ratio is presently 13.40%.

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.